CureVac N.V. secured funding with GSK amid financial struggles, while a key patent win boosts stock. Click for why my ...

A new study conducted by researchers at Hokkaido University has unveiled a novel class of zwitterionic phospholipids capable ...

Scientists in The Wistar Institute lab of David B. Weiner, Ph.D., have described a next-generation vaccination technology ...

The United States led the world in developing the technology that beat the COVID-19 pandemic. Action from lawmakers may leave ...

In pediatric patients aged 6 months to 5 years, the VE of mRNA-1273 against symptomatic infection was modest after a single dose and strong after a second dose.

CureVac's amended patent survives BioNTech's challenge as EPO upholds validity. A German court will decide on infringement in ...

The European Patent Office declared a patent owned by CureVac , valid, after a challenge from drugmaker BioNTech , the company said on Thursday.

EQS-News: GeoVax, Inc. / Key word (s): Financial GeoVax Reports 2024 Year-End Financial Results and Provides Business Update 27.03.2025 / 21:06 CET/CEST The issuer is solely responsible for the ...

Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S.

What’s Up With mRNA Research? A research nurse holds an injection of a BioNTech mRNA cancer immunotherapy for non-small cell ...

The inquiry is looking into a politically explosive suggestion that Pfizer delayed announcing a successful vaccine against ...

USPTO Finds Claims Of Two Of Moderna’s mRNA Patents Unpatentable: What’s Next In The Vaccine Wars? Legal News and Analysis - ...